Trial · NCT00565916
Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism
NCT00565916, Not applicable, Terminated, Washington University School of Medicine; results first posted 2018-10-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism. Trials, record NCT00565916. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00565916
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism
- NCT number
- NCT00565916
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 22 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Postmenopausal Syndrome
- Interventions
- Estrogen, Progesterone, Placebo
- First posted
- 2007-11-30
- Last updated
- 2018-10-16
- Results first posted
- 2018-10-16
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Had an Increase in Myocardial Fatty Acid Utilization. | 3 days | Measurements of myocardial fatty acid utilization and oxidation with C\[11\]-Palmitate and PET in healthy postmenopausal women who take either estrogen alone or with progesterone. The primary outcome measure was designed to determine prospectively whether estrogen will increase the heart's fatty acid utilization and whether progestins will attenuate this effect, in a manner similar to what was seen in an observational study of hormone replacement therapy (HRT) in post-menopausal women. To this end, we had anticipated enrolling 30 healthy post-menopausal women for assessment of cardiac fatty acid metabolism using positron emission tomography (PET) and radioactive C\[11\]-Palmitate both before and after 3 days of hormone replacement therapy. These volunteers were to be randomized to receive either estrogen alone (E) or combined estrogen/progesterone (EP). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Had an Increase in Myocardial Fatty Acid Utilization. | 3 days | 22 healthy post'menopausal women. These volunteers were to be randomized to receive either estrogen alone, or combined estrogen/progesterone. Efforts were made to access the data, PI left institution and there is no access to the data. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Had an Increase in Myocardial Fatty Acid Utilization. | Estrogen Plus Progesterone | NA | Participants | ||
| Number of Participants That Had an Increase in Myocardial Fatty Acid Utilization. | Estrogen Plus Placebo | NA | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hormone Replacement Therapy (HRT): Estrogen Plus Progesterone | 11 | |
| Overall Study | STARTED | Estrogen Plus Placebo | 11 | |
| Overall Study | COMPLETED | Hormone Replacement Therapy (HRT): Estrogen Plus Progesterone | 11 | |
| Overall Study | COMPLETED | Estrogen Plus Placebo | 11 | |
| Overall Study | NOT COMPLETED | Hormone Replacement Therapy (HRT): Estrogen Plus Progesterone | 0 | |
| Overall Study | NOT COMPLETED | Estrogen Plus Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Estrogen Plus Progesterone | 0 | 11 |
| Total, all-cause mortality | Estrogen Plus Placebo | 0 | 11 |
| Total, other adverse events | Estrogen Plus Progesterone | 0 | 11 |
| Total, other adverse events | Estrogen Plus Placebo | 0 | 11 |
| Total, serious adverse events | Estrogen Plus Progesterone | 0 | 11 |
| Total, serious adverse events | Estrogen Plus Placebo | 0 | 11 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL077179 | Role of Estrogen/SERMs on Cardiac Fatty Acid Metabolism | SOTO, PABLO F | WASHINGTON UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2004 to 2008 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Estrogen Plus Progesterone vs Estrogen Plus Placebo: deaths from any cause | Trial comparisons |
| Estrogen Plus Progesterone vs Estrogen Plus Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00565916
GET https://conductscience.org/api/trials/v1/NCT00565916/registered